chang drug price polici
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
merck combin wide line-up high-margin drug
pipelin new drug ensur strong return invest
capit long term merck worst
patent cliff remov heighten gener
competit compani experienc past year
sever year moder research develop
product merck drug develop strategi yield
merck new product mitig gener competit
offset recent major patent loss particular keytruda
cancer repres key blockbust multi-billion-dollar
potenti hold first-mov advantag one largest
cancer indic non-smal cell lung cancer also expect
new cancer drug combin propel merck overal
drug sale howev expect intens competit cancer
market sever competit drug like report import
clinic data headwind includ
gener competit notabl cardiovascular drug zetia
vytorin like creat drag overal growth
migrain safeti question end
sever year mix result merck product
improv compani shift toward area unmet
medic need owe side effect lack compel efficaci
merck experienc major setback cardiovascular diseas
drug anacetrapib tredapt rolofyllin tra along
develop osteoporosi drug odanacatib despit
setback merck solid success includ success
launch drug keytruda oncolog follow
success merck shift focu toward area unmet medic
need specialty-car area keytruda lead new
direct expect keytruda leadership non-smal cell lung
cancer key driver growth compani next
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note gaap report dilut ep differ model due
merck make pharmaceut product treat sever condit
number therapeut area includ cardiovascular diseas asthma
cancer infect within cancer firm immuno-oncolog platform
grow major contributor overal sale compani also
substanti vaccin busi treatment prevent hepat
pediatr diseas well hpv shingl addit merck sell
anim health-rel drug geograph perspect close
firm sale gener unit state
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
outlook chang drug price polici
initi result super tuesday democrat primari
show increas support former vice presid biden
whose nomin would reduc likelihood signific
drug price polici chang line
expect dont expect major chang fair
valu estim moat rate drug biotech
industri base result continu view
industri under-valued averag
due partli excess concern around potenti major
drug polici chang note elect result
bigger impact healthcar insur servic
relief ralli health insur servic provid
drug side movement toward moder
democrat biden like mean minor drug polici
chang reduc chanc medicar
scenario champion biden key oppon sen
berni sander would like significantli reduc
drug price negoti power one-pay
system elect support shift toward biden
believ like chang drug price polici
reform center around senat bill prescript drug
price reduct act pdpra howev still believ
propos hold less chanc pass base
mix level support parti havent
includ passag bill model howev
pass estim aggreg hit brand
drug sale medicar inflat price cap part
redesign propos bill believ drug
biotech industri could adapt headwind
minor impact cash flow partli cost cut
increas volum base lower price mandat
bill importantli bill would limit out-of-pocket
payment patient medicar would like help
appeas demand lower drug price
potenti drug polici chang key element
esg analysi drug firm pleas see recent
healthcar observ esg risk affect moat
pharma morningstar
decreas fair valu estim
per share per share base incorpor higher long-term
legal cost review product govern trend
industri believ merck like face slightli
legal cost defend product portfolio
overal merck look well posit cancer drug
keytruda lynparza well hpv vaccin gardasil
expect keytruda gain lion share late stage
non-smal cell lung cancer nsclc market well close
adjuv nsclc market continu
expect steadi long-term growth entir firm partli
driven solid outlook cancer drug keytruda
lesser extent strong outlook hpv vaccin gardasil
larg intern market keytruda key merck
valuat expect leader
immuno-oncolog market expect drug reach peak
sale billion larg base strong efficaci
sever cancer type includ lung head neck
melanoma sever cancer indic look
entir compani next five year expect
merck post annual top-lin growth new
drug offset drug lost gener competit potenti
game changer growth rate includ compani
pipelin immuno-oncolog drug move quickli
clinic develop merck still face gener
competit older drug remicad immunolog zetia
cardiovascular vytorin cardiovascular
heaviest near-term patent loss close four year
gener like diabet drug januvia howev
believ pipelin drug growth exist drug
off-set gener headwind overal expect improv
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
sale come keytruda impact competit
new clinic data significantli affect import drug
merck lastli ad potenti
healthcar polici reform relat drug price bear
case creat addit pressur
patent economi scale power intellectu
base buoy merck busi keep well shield
competit bedrock merck wide moat
patent protect continu keep competitor
bay compani strive introduc next
gener drug compani enorm cash
flow support power salesforc sell
current market drug also serv deterr
develop drug compani seek launch compet
opportun extern develop drug cash flow
also put compani rare posit support
approxim million need averag
bring new drug market power
merck research laboratori still hold
vast databas knowledg help compani
maintain leadership posit drug discoveri
develop also compani entrench
immuno-oncolog area strengthen
merck competit posit drug carri
strong price power area unmet medic need lastli
merck strong entrench vaccin add layer
competit protect intellectu properti cost
advantag firm large-scal product enabl
face deterior moat trend past merck
competit advantag stabil patent protect
still shield major drug competit
compani develop enough new drug off-set
margin near term overal sale repres
specialty-ori drug carri strong price
power need less market support
maintain uncertainti rate merck
medium overal larg base cash flow
divers inelast product portfolio rate merck
uncertainti medium view merck uncertainti
medium rather low due increas import
keytruda look well posit partli reduc
merck product divers cash flow scenario
analysi assum base-cas fair valu estim
bull case probabl bear
rel base case scenario analysi show
modest varianc henc medium uncertainti rate
key factor affect scenario analysi includ
degre success brand drug pipelin along
magnitud market pressur current market
drug within portfolio import driver
valuat keytruda cancer close quarter
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
eventu patent loss pipelin side merck made
strateg shift acceler move focu
unmet medic need specialti care area
debilit lethal diseas strateg shift help
increas product fight back
follow three neg trend first post-vioxx era
food drug administr grown increasingli
risk-sensit primary-car diseas tend approv
safe drug drug highli need area
cancer second insur compani steadili
reduc coverag follow-on drug forc drug firm
push true innov reduc power
distribut network lastli govern
develop market increasingli use compar
effect program aggress push
price negoti respons challeng merck
strateg focu toward unmet medic need
increas probabl success regulatori agenc
support stronger pharmaceut price power
payer fewer altern exist treatment area
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
okeytruda look best posit immuno-
advantag import indic first-lin non-
landscap buoy
oth growth merck high margin cancer drug
help expand compani overal oper
omerck support strong dividend yield look
secur base wide diversifi portfolio drug
ooutsid immuno oncolog merck need increas
number late-stag pipelin drug
owhil major patent loss behind
compani firm face gener competit
januvia potenti earli
oadvanc oncolog happen quickli
could caus disrupt merck lead growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
merck remain solid financi foot compani
close debt/capit strong cash flow
expect next sever year
strengthen balanc sheet howev merck signal
strong willing make acquisit histor
tend make sever bolt-on acquisit year
given merck made major acquisit sinc
schering-plough deal expect make
larger acquisit next two three year beyond
acquisit expect steadi futur dividend support
pay-out ratio close rel adjust
merck near-term risk larg center market accept
new drug like pharmaceut compani merck
face regulatori risk fda product delay
nonapprov could hurt stock also grow power
manag care price-sensit
addit merck face remain legal risk
vioxx major plaintiff particip
billion settlement holdout could ring major
addit settlement also litig risk remain
patient took one-tim blockbust fosamax
osteoporosi medicin link infrequ
seriou side effect lastli grow success
keytruda increas firm depend drug
growth could becom problemat side
effect show new therapi emerg quickli treat
cancer howev overal view merck uncertainti
medium given wide divers larg inelast drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
mr kenneth frazier ceo/chairman board/
repres date owner name posit common share held report holder issuer
capit research manag compani
share
fund
share
fund
ken frazier took ceo dick clark begin
appoint chairman board late
clark near retir age view
new leader continu merck past strategi
red flag shift leadership approach frazier
part success strategi guid clark frazier
almost two decad experi merck across
major divis posit well lead
compani also deserv much credit
success handl vioxx litig held
merck gener counsel posit major
litig merck board pack current retir
ceo lead quid pro quo compens
top execut
rate compani stewardship standard merck
shown reason use capit purchas
schering-plough fair price brought sever
import pipelin product includ keytruda
allow cost-cut opportun hand
billion acquisit cubist seem like stretch
make valuat work especi announc
sooner-than-expect patent loss key drug cubicin
merck heavi fund past decad
produc mix result sever import new drug
also mani failur howev compani shift
 focu toward area specialti care away
primari care continu support improv
product success keytruda exampl
new focu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
increas growth outlook keytruda depend
plan maintain fair valu estim merck
follow slightli disappoint fourth-quart earn
solid guidanc along surpris spin-off
announc sever legaci drug platform includ
women health biosimilar continu view
compani under-valued market fulli
appreci firm strong posit immuno-oncolog
led keytruda addit dont expect spin-off
older product line impact merck wide moat
support strong portfolio drug gener cash
flow develop next gener drug
merck decis divest older legaci drug
billion expect sale close sale
set faster sale growth focus
compani less product sale depend
keytruda grow merck plan spin-off
first half enabl slightli faster growth
remain compani spin-off give merck
billion special dividend expect
merck use share buyback small tuck-in
acquisit howev loss legaci drug
expect growth keytruda expect merck
depend keytruda grow almost total
sale current keytruda hold
excel outlook increas depend one drug
turn quarter overal sale growth
quarter led cancer drug keytruda
expect keytruda lead overal growth next sever
year support lead efficaci lung cancer like
new indic earlier use set lower sale
human papillomaviru vaccin gardasil partli due shift
inventori weigh quarter expect
vaccin return growth driven intern market
look concern around price pressur
pharmaceut believ merck
posit portfolio vaccin drug howev
spin-off legaci product increas merck
sale price concern
elev key element esg analysi
merck price posit aspect esg
includ legal issu pleas see recent healthcar
observ esg risk affect moat valuat
pharma morningstar sustainalyt offer
sustainalyt esg risk methodolog
point opportun pharma/biotech jan
sustainalyt
own
collabor broaden deepen
esg analysi incorpor environment social
govern factor valuat analysi
pharma focus
materi esg issu social realm think
firm expos esg risk morningstar
conclud valuation-affect esg risk brand
drug firm center price risk larg litig
provid comprehens evalu support
mostli wide moat rate industri
overal see under-valued name roch
biomarin lowest exposur esg-rel
strategi focu sever diseas lower price
pressur includ base case alreadi factor much
potenti headwind intern benchmark
price could test medicar part
biomarin global price strategi rare-diseas drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
well seriou natur condit limit futur
price litig risk despit high price tag
medicar exposur minim
limit distribut limit re-import also canada would
like support plan low drug price would
like face rise pressur support price
also like sanofi
valuat esg risk johnson johnson eli lilli look
least compel us base litig risk
valuat look under-valued
implement scope drug target potenti
re-import limit exclud drug biolog
inject drug drug subject fda risk evalu
mitig strategi rem drug group repres
core area focu new drug reach market
detail analysi price litig issu
top pharma name
coverag see januari
healthcar observ esg risk affect moat
pharma morningstar
trump propos drug reimport look limit
potenti lower drug price dec
trump administr move allow drug import
canada look challeng implement
limit scope dont expect major chang
fair valu estim drug biotechnolog
industri view administr move driven
polit motiv anoth elect cycl draw
near rather major structur shift influenc drug
price continu view price power drug
strong central pillar support moat rate
larg drug biotechnolog compani
import action propos
human servic juli propos rule
releas fda decemb dont view
plan major driver lower drug price think
implement chang would difficult
practic hard reconcil safeti provis
part feder track-and-trac system stop
counterfeit drug ensur enough drug-firm suppli low
price canada anoth concern drug firm could
congress support drug re-import past
safe implement propos limit
enact expect similar limit around
recent propos given complex distribut
differ drug label countri see poor
prospect wide use drug re-import
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued within
report highlight impact enact chang
drug payment increas discount
medicar part doughnut hole sale also review
depth drug polici propos council
econom advisor budget
merck post strong aid keytruda vaccin
anim health drug stock look under-valued
merck report strong third-quart result ahead
capiq consensu expect plan
increas fair valu estim base robust result
continu view merck under-valued market
merck strength oncolog coupl solid traction
vaccin anim healthcar support firm wide
potenti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
quarter total sale increas oper year
year led cancer drug keytruda
expect continu steadi gain drug keytruda first-
mover advantag largest market segment first-lin
lung cancer combin excel efficaci data
enabl drug gain lion share
competit data bristol opdivo yervoy
checkmat look potenti competit small
subseg market cant take chemotherapi
posit top-lin data announc
astra bristol studi poseidon checkmat
respect skeptic forthcom
detail data behind studi provid strong enough
data displac merck entrench also keytruda
new indic renal cancer adjuv melanoma
esophag cancer drive near-term growth
longer term expect favor data adjuv lung
cancer add signific growth potenti
beyond keytruda merck cancer drug lynparza
lenvima vaccin anim health product continu
post steadi gain continu next
sever year strong efficaci data behind cancer drug
robust demand china vaccin set solid growth
strong growth sale high-margin drug help
merck oper margin expect trend continu
model almost basi point margin
expans next five year
early-stag pipelin see encourag
data come oncolog platform believ next
major develop merck pipelin
keytruda adjuvant/neoadjuv use especi focus
lung cancer complet review outlook
immuno-oncolog drug earlier line usag pleas
see recent report immuno-oncolog drug adjuv
lung frontier strengthen moat
overview merck pipelin asset pleas see
remain secur innov counter price gener
headwind acceler
bristol lung cancer data favor checkmat
merck lead look secur sep
bristol-my report posit final data part one
chemotherapi first-lin non-smal cell lung cancer
nsclc dont expect signific chang
fair valu base data continu view bristol
under-valued acquisit celgen pipelin
fulli appreci market also continu
expect bristol focu oncolog drug drive strong
price power reinforc compani wide moat
cross-trial comparison drawback efficaci
bristol combin opdivo plu yervoy checkmat
doesnt look well posit merck keytruda-
plu chemotherapi howev patient
express approxim three quarter
patient adamantli use chemotherapi especi
due neutropenia anemia side effect issu bristol
combin offer best altern bristol
data low expressor less express
look competit trial design may limit
inclus sub-seg data label also data
squamou patient also
look competit
nevertheless merck control first-mov
advantag lead efficaci data believ keytruda
gain close first-lin metastat nsclc
market follow roch tecentriq bristol
opdivo includ yervoy one last remain
studi patient popul bristol checkmat
read first-half studi
includ chemotherapi prime help patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
aggress form diseas addit
control crossov import studi
believ part reason merck keytruda shown
rel strong overal surviv data relat limit
amount crossov chemotherapi arm
beyond first-lin nsclc expect next wave
import immuno-oncolog data address earli stage
cancer adjuv neoadjuv earli stage lung
cancer alon project close billion annual sale
probabl weight estim
probabl success earli treatment set
complet overview adjuvant/neoadjuv lung
market immuno oncolog drug pleas see report
titl immuno-oncolog drug adjuv lung
frontier strengthen moat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
